Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

(2017) Clyde W. Yancy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition

(2017) Subodh Verma et al.   JAMA Cardiology

Treatment of diabetes and heart failure: joint forces

(2016) Karl Swedberg et al.   EUROPEAN HEART JOURNAL

Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus

(2016) Nikolaus Marx et al.   EUROPEAN HEART JOURNAL

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

2016 European Guidelines on cardiovascular disease prevention in clinical practice

(2016) Massimo F. Piepoli et al.   EUROPEAN HEART JOURNAL

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

(2016) Piotr Ponikowski et al.   EUROPEAN HEART JOURNAL

Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and DeathCLINICAL PERSPECTIVE

(2015) Matthew A. Cavender et al.   CIRCULATION

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls

(2015) Anne Pernille Ofstad et al.   Journal of Diabetes

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

(2014) Bernard Zinman et al.   Cardiovascular Diabetology

Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology

(2013) Richard M Cubbon et al.   Diabetes & Vascular Disease Research

Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry

(2013) Isabelle Johansson et al.   EUROPEAN JOURNAL OF HEART FAILURE

Prediction of Incident Heart Failure in General Practice

(2012) Sunil K. Agarwal et al.   Circulation-Heart Failure

Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial

(2012) Satyam Sarma et al.   EUROPEAN JOURNAL OF HEART FAILURE

Validation of the Health ABC Heart Failure Model for Incident Heart Failure Risk Prediction

(2010) Andreas Kalogeropoulos et al.   Circulation-Heart Failure

Left Ventricular Diastolic Function in Type 2 Diabetes Mellitus

(2009) Mikael Kjaer Poulsen et al.   Circulation-Cardiovascular Imaging

Subclinical left ventricular dysfunction in asymptomatic diabetic patients assessed by two-dimensional speckle tracking echocardiography: correlation with diabetic duration

(2009) H. Nakai et al.   European Journal of Echocardiography

Incident Heart Failure Prediction in the Elderly

(2008) Javed Butler et al.   Circulation-Heart Failure

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme

(2008) M. R. MacDonald et al.   EUROPEAN HEART JOURNAL